We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

63 hedge funds and large institutions have $22.6M invested in IVERIC bio, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

451% more call options, than puts

Call options by funds: $248K | Put options by funds: $45K

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

7% less funds holding

Funds holding: 6863 (-5)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

38% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 24

50% less capital invested

Capital invested by funds: $44.9M → $22.6M (-$22.3M)

Holders
63
Holders Change
-5
Holders Change %
-7.35%
% of All Funds
1.4%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
7
Increased
15
Reduced
24
Closed
11
Calls
$248K
Puts
$45K
Net Calls
+$203K
Net Calls Change
-$96K
Name Holding Trade Value Shares
Change
Change in
Stake
SEI Investments
26
SEI Investments
Pennsylvania
$66K
Creative Planning
27
Creative Planning
Kansas
$65K
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$52K
State Street
29
State Street
Massachusetts
$50K
Wells Fargo
30
Wells Fargo
California
$47K +$7.01K +3,618 +10%
BIM
31
Bogle Investment Management
Massachusetts
$44K -$15.2K -7,834 -18%
Rockefeller Capital Management
32
Rockefeller Capital Management
New York
$44K
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$34K -$25.3K -13,049 -31%
Russell Investments Group
34
Russell Investments Group
United Kingdom
$30K -$27.9K -14,390 -37%
PAM
35
Panagora Asset Management
Massachusetts
$30K -$917 -473 -2%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$28K -$49.2K -25,370 -52%
TRCT
37
Tower Research Capital (TRC)
New York
$24K +$12.8K +6,601 +51%
Jane Street
38
Jane Street
New York
$23K +$37K +19,069 New
GF
39
Gabelli Funds
New York
$22K -$3.88K -2,000 -10%
Squarepoint
40
Squarepoint
New York
$18K -$12.4K -6,412 -30%
Goldman Sachs
41
Goldman Sachs
New York
$16K -$50.5K -26,067 -66%
ARTA
42
A.R.T. Advisors
New York
$15K -$11.3K -5,812 -32%
VF
43
Virtu Financial
New York
$12K +$20.2K +10,404 New
Group One Trading
44
Group One Trading
Illinois
$4K -$15.1K -7,790 -70%
CG
45
Cutler Group
California
$3K
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$3K +$419 +216 +9%
Federated Hermes
47
Federated Hermes
Pennsylvania
$2K -$1.77K -914 -41%
EWM
48
Endurance Wealth Management
Rhode Island
$2K
UBS Group
49
UBS Group
Switzerland
$2K +$1.07K +553 +104%
Macquarie Group
50
Macquarie Group
Australia
$1K -$61.9K -31,954 -97%

ISEE Hedge Fund Activity: Q4 2018 in Review

63 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q4 2018, worth a combined $22.6M — down 50% from $44.9M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ISEE and 7 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 15 added.

The largest buyer was Stonepine Capital Management, adding an estimated $3.39M. The largest seller was AJO LP, exiting entirely with an estimated $2.57M sold.

  • 63 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q4 2018, down from 68 in Q3 2018.
  • Funds reported $22.6M of IVERIC bio, Inc. Common Stock stock for Q4 2018, down 50% quarter-over-quarter.
  • 7 funds opened new IVERIC bio, Inc. Common Stock positions in Q4 2018 and 11 closed out, a net change of -4 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q4 2018 was Stonepine Capital Management, an estimated $3.39M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q4 2018 was AJO LP, an estimated $2.57M sold.

Based on aggregated 13F filings for Q4 2018.